Oct, 12 2018 14:48 JST

Source: Eisai

Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China


TOKYO, Oct, 12 2018 - (JCN Newswire) - Eisai Co., Ltd. has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai's antiepileptic drug (AED) perampanel (generic name, product name: Fycompa) as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older. This NDA is the first to be submitted for perampanel in China.

This application for perampanel in partial onset seizures in China was based on the results of three Phase III clinical studies conducted mainly in Europe and the United States, as well as the results of a Phase III clinical study (Study 335) conducted mainly in Asia including China and Japan.

In China it is estimated that there are approximately 9 million patients with epilepsy, with approximately 60% being affected by partial-onset seizures, and 40% of these patients with partial-onset seizures require adjunctive treatment.(1) As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs,(2) this is a disease with significant unmet medical need.

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. Administered orally once-daily, it is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes.

Perampanel has been approved in over 55 countries around the world as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In addition, perampanel has been approved in over 50 countries around the world as an adjunctive treatment for primary generalized tonic clonic seizures in patients with epilepsy 12 years of age and older. In the United States, perampanel is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.

Eisai considers neurology including epilepsy, a therapeutic area of focus, and is striving to deliver perampanel to patients in China as soon as possible. In pursuit of our mission to provide "seizure freedom" to a greater number of patients living with epilepsy, Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

About perampanel (generic name, product name: Fycompa)

Perampanel is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is available in tablet form to be taken once daily orally at bedtime. In addition, an oral suspension formulation has been approved in the United States.

Perampanel is currently approved in more than 55 countries and territories, including the United States, Japan, in Europe and in Asia as adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. An application seeking approval for use in the treatment of partial-onset seizures has now been filed in China. In addition, perampanel has been approved in more than 50 countries, including the United States, Japan, in Europe and in Asia for treatment as an adjunctive therapy for primary generalized tonic clonic seizures in patients with epilepsy 12 years of age and older. In the United States, perampanel is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older.

Furthermore, Eisai is conducting a global Phase III clinical study (Study 338) for the agent in patients with seizures associated with Lennox-Gastaut syndrome. In Japan and Europe, Eisai is conducting a Phase III study in pediatric patients with epilepsy (Study 311). Additionally, a Phase III study of perampanel as monotherapy in untreated patients with partial-onset seizures 12 years of age and older is being conducted in Japan (Study 342).

About Epilepsy

Epilepsy affects approximately 3.4 million people in the United States, 1 million people in Japan, 6 million people in Europe, 9 million people in China, and approximately 60 million people worldwide. As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs,(2) this is a disease with significant unmet medical need.

Epilepsy is broadly categorized by seizure type, with partial-onset seizures accounting for approximately 60% of epilepsy cases and generalized seizures accounting for approximately 40%. In a partial-onset seizure, an abnormal electrical disturbance occurs in a limited area of the brain, and may subsequently spread throughout the brain, becoming a generalized seizure (known as a secondarily generalized seizure). In a generalized seizure, abnormal electrical disturbances occur throughout the brain, and can be followed by a loss of consciousness or physical symptoms manifested throughout the whole body.

(1) Clinical Guideline 2015 in China
(2) "The Epilepsies and Seizures: Hope Through Research. What are the epilepsies?" National Institute of Neurological Disorders and Stroke, accessed May 24, 2016
(3) Nishida T., et al. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018; 137:392-399


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. +81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Receives "IR Grand Prix Award"
November 14 2018 12:30 JST
 
Eisai Launches Lenvima (Lenvatinib) in China
November 12 2018 11:51 JST
 
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
November 09 2018 08:08 JST
 
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence
November 08 2018 14:38 JST
 
Eisai Commences Full-Scale Operation of New Suzhou Plant in China
November 08 2018 08:43 JST
 
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD
October 29 2018 08:45 JST
 
Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease
October 26 2018 08:32 JST
 
Eisai and Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease
October 26 2018 07:03 JST
 
Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research
October 25 2018 08:05 JST
 
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide
October 23 2018 14:13 JST
 
More Press release >>

Latest Press Release


More Latest Release >>